Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Drops By 33.8%

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) saw a large decline in short interest in the month of October. As of October 31st, there was short interest totalling 109,800 shares, a decline of 33.8% from the October 15th total of 165,900 shares. Approximately 2.3% of the company’s stock are sold short. Based on an average trading volume of 65,200 shares, the short-interest ratio is presently 1.7 days.

Hedge Funds Weigh In On Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC acquired a new stake in shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned approximately 11.30% of Brainstorm Cell Therapeutics at the end of the most recent quarter. 14.33% of the stock is owned by institutional investors.

Brainstorm Cell Therapeutics Stock Up 7.1 %

Shares of NASDAQ:BCLI opened at $1.21 on Friday. The stock’s 50 day moving average is $2.53 and its 200-day moving average is $4.71. Brainstorm Cell Therapeutics has a twelve month low of $1.05 and a twelve month high of $11.89. The firm has a market capitalization of $6.44 million, a price-to-earnings ratio of -0.35 and a beta of 0.40.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.60). During the same quarter last year, the firm earned ($4.05) EPS. Equities research analysts anticipate that Brainstorm Cell Therapeutics will post -2.85 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com downgraded Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.